Published in Eur Urol on May 20, 2010
Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol (2009) 2.25
Population screening for prostate cancer: an overview of available studies and meta-analysis. Int J Urol (2011) 2.11
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol (2008) 2.00
Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.80
Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol (2007) 1.44
Contemporary minimally-invasive extended pelvic lymph node dissection for prostate cancer before curative radiotherapy: prospective standardized analysis of complications. Int J Urol (2014) 1.42
Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys (2010) 1.33
Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys (2008) 1.20
Soluble cadherins as cancer biomarkers. Clin Exp Metastasis (2007) 1.20
Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol (2006) 1.16
Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol (2006) 1.15
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol (2014) 1.14
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer (2014) 1.13
Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients. Cancer (2005) 1.13
Analysis of prostate bed motion using daily cone-beam computed tomography during postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.13
Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer (2012) 1.11
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol (2006) 1.10
Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys (2009) 1.07
Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate (2014) 1.05
A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.02
Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiother Oncol (2009) 1.01
High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol (2011) 1.01
Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol (2008) 0.99
Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation. Strahlenther Onkol (2009) 0.96
Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome. Radiother Oncol (2013) 0.95
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer (2010) 0.94
Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys (2012) 0.94
Radiotherapy and surgery-an indispensable duo in the treatment of retroperitoneal sarcoma. Cancer (2011) 0.93
Delineation of the postprostatectomy prostate bed using computed tomography: interobserver variability following the EORTC delineation guidelines. Int J Radiat Oncol Biol Phys (2011) 0.93
Evaluation of the efficacy and safety of Salvia officinalis in controlling hot flashes in prostate cancer patients treated with androgen deprivation. Phytother Res (2011) 0.88
Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFβ1 gene. Int J Radiat Oncol Biol Phys (2012) 0.88
Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10. Int J Radiat Oncol Biol Phys (2013) 0.87
Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity. Int J Radiat Oncol Biol Phys (2012) 0.86
Evaluation of the Sinmed Mastercouch as replacement for a standard couch. Radiother Oncol (2005) 0.84
Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases. Neurol Sci (2012) 0.84
Short term toxicity profile for 32 sinonasal cancer patients treated with IMRT. Can we avoid dry eye syndrome? Radiother Oncol (2002) 0.83
Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. Int J Radiat Oncol Biol Phys (2008) 0.83
The role of nuclear medicine in the prediction and detection of radiation-associated normal pulmonary and cardiac damage. J Nucl Med (2003) 0.82
Nomograms to predict late urinary toxicity after prostate cancer radiotherapy. World J Urol (2013) 0.82
High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys (2011) 0.82
Salvage radiotherapy: a plea for dose-escalation with intensity-modulated radiotherapy. Eur J Cancer (2012) 0.82
Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer. Int J Radiat Oncol Biol Phys (2009) 0.80
Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol (2007) 0.80
Prostate cancer pain management: EAU guidelines on pain management. World J Urol (2012) 0.80
Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: toxicity and matched case comparison with postoperative prostate bed-only radiotherapy. Radiother Oncol (2013) 0.79
Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer. Adv Urol (2011) 0.79
Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched study. Int J Gynecol Cancer (2012) 0.79
Postoperative radiotherapy for adenocarcinoma of the ethmoid sinuses: treatment results for 47 patients. Int J Radiat Oncol Biol Phys (2002) 0.79
Point/counterpoint. High intensity focused ultrasound may be superior to radiation therapy for the treatment of early stage prostate cancer. Med Phys (2011) 0.78
Volumetric modulated arc therapy for delivery of prostate radiotherapy: in regard to Palma et al. (Int J Radiat Oncol Biol Phys 2008;70:996-1001). Int J Radiat Oncol Biol Phys (2009) 0.78
A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol (2011) 0.78
Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience. Int J Radiat Oncol Biol Phys (2010) 0.77
PCA: prostate cancer, patient-centred approach or both? BJU Int (2012) 0.76
Completion surgery after intensity-modulated arc therapy in the treatment of locally advanced cervical cancer: feasibility, surgical outcome, and oncologic results. Int J Gynecol Cancer (2013) 0.76
Prostate cancer: AUA-ASTRO guidelines for post-RP radiation fail to go nuclear. Nat Rev Urol (2013) 0.76
Developments in external beam radiotherapy for prostate cancer. Urology (2013) 0.76
Post-irradiation sarcoma after external beam radiation therapy for localized adenocarcinoma of the prostate. Tumori (2005) 0.76
Improving positioning in high-dose radiotherapy for prostate cancer: safety and visibility of frequently used gold fiducial markers. Int J Radiat Oncol Biol Phys (2011) 0.75
Gold(I) complexes of tetrathiaheterohelicene phosphanes. Inorg Chem (2013) 0.75
Image-guided radiation therapy: many roads lead to Rome? Int J Radiat Oncol Biol Phys (2008) 0.75
Intensity-modulated radiotherapy: the gold standard for postprostatectomy irradiation? Eur Urol (2011) 0.75
Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol 2011;59:1009-18. Eur Urol (2011) 0.75
Androgen Receptor Gene Copy Number and Protein Expression in Treatment-Naïve Prostate Cancer. Urol Int (2017) 0.75
Upper limit to the ultimate achievable emission wavelength in near-IR emitting cyclometalated iridium complexes. Photochem Photobiol Sci (2017) 0.75
Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr Opin Urol (2017) 0.75
An immobilized antibody targeting N-cadherin facilitates spread of N-cadherin-positive tumour cells. Anticancer Res (2012) 0.75
Anxiety, depression and informed consent in patients referred to a radiotherapy department. Tumori (2003) 0.75
Theoretical design of substituted tetrathia-[7]-helicenes with large second-order nonlinear optical responses. Chemphyschem (2004) 0.75
The oncologic role of local treatment in primary metastatic prostate cancer. World J Urol (2014) 0.75
Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience. Acta Oncol (2014) 0.75
Can a cure be achieved with taxane-based chemotherapy plus surgery in patients with primary mediastinal non-seminomatous germ cell tumors and progression or relapse despite first-line chemotherapy? Onkologie (2010) 0.75
Early biomarkers related to secondary primary cancer risk in radiotherapy treated prostate cancer patients: IMRT versus IMAT. Radiother Oncol (2013) 0.75
Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including 1759 patients treated during two decades (1980-1998). Int J Radiat Oncol Biol Phys (2002) 0.75
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? Curr Opin Urol (2017) 0.75
Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. BJU Int (2014) 0.75